Anticancer activity of thymoquinone in breast cancer cells: Possible involvement of PPAR-γ pathway

Biochemical Pharmacology

Volumn 82, Issue 5, 2011, Pages 464-475

  Woo, Chern Chiuh ^a   Loo, Ser Yue ^a,b   Gee, Veronica ^c   Yap, Chun Wei ^c   Sethi, Gautam ^a   Kumar, Alan Prem ^a,b   Benny Tan, Kwong Huat ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Apoptosis; Breast cancer; Molecular docking; PPAR ; Thymoquinone

Indexed keywords

CASPASE 7; CASPASE 8; CASPASE 9; DOXORUBICIN; FLUOROURACIL; LIPOCORTIN 5; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; THYMOQUINONE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER PREVENTION; CELL CYCLE G1 PHASE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; HORMONAL REGULATION; HORMONE ACTION; HUMAN; HUMAN CELL; MOLECULAR DOCKING; NONHUMAN; PLASMID; PRIORITY JOURNAL;

ANILIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BENZOQUINONES; BREAST NEOPLASMS; CASPASES; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; NEOPLASM INVASIVENESS; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 79960929095     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.05.030     Document Type: Article

References (61)

1. Salem ML. Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Int Immunopharmacol 2005;5:1749-70. (Pubitemid 41594584)
2. Burits M, Bucar F. Antioxidant activity of Nigella sativa essential oil. Phytother Res 2000;14:323-8. (Pubitemid 30655515)
3. Hajhashemi V, Ghannadi A, Jafarabadi H. Black cumin seed essential oil, as a potent analgestic and anti-inflammatory drug. Phytother Res 2004;18:195-9. (Pubitemid 38568744)
4. Badary OA, Taha RA, Gamal el-Din AM, Abdel-Wahab MH. Thymoquinone is a potent superoxide anion scavenger. Drug Chem Toxicol 2003;26:87-98. (Pubitemid 36597385)
5. El Gazzar M, El Mezayen R, Marecki JC, Nicolls MR, Canastar A, Dreskin SC. Antiinflammatory effect of thymoquinone in a mouse model of allergic lung inflammation. Int Immunopharmacol 2006;6:1135-42.
6. Gali-Muhtasib H, Ocker M, Kuester D, Krueger S, El-Hajj Z, Diestel A, et al. Thymoquinone reduces mouse colon tumor cell invasion and inhibits tumor growth in murine colon cancer models. J Cell Mol Med 2008;12: 330-42.
7. Kaseb AO, Chinnakannu K, Chen D, Sivanandam A, Tejwani S, Menon M, et al. Androgen receptor- and E2F-1-targeted thymoquinone therapy for hormonerefractory prostate cancer. Cancer Res 2007;67:7782-8. (Pubitemid 47281372)
8. Roepke M, Diestel A, Bajbouj K, Walluscheck D, Schonfeld P, Roessner A, et al. Lack of p53 augments thymoquinone-induced apoptosis and caspase activation in human osteosarcoma cells. Cancer Biol Ther 2007;6:160-9. (Pubitemid 46641618)
9. Ivankovic S, Stojkovic R, Jukic M, Milos M, Milos M, Jurin M. The antitumor activity of thymoquinone and thymohydroquinone in vitro and in vivo. Exp Oncol 2006;28:220-4. (Pubitemid 44735913)
10. El-Mahdy MA, Zhu Q, Wang QE, Wani G, Wani AA. Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myoloblastic leukemia HL-60 cells. Int J Cancer 2005;117: 409-17. (Pubitemid 41429564)
11. Gali-Muhtasib H, Diab-Assaf M, Boltze C, Al-Hmaira J, Hartig R, Roessner A, et al. Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism. Int J Oncol 2004;25:857-66.
12. El-Najjar N, Chatila M, Moukadem H, Vuorela H, Ocker M, Gandesiri M, et al. Reactive oxygen species mediate thymoquinone-induced apoptosis and activate ERK and JNK signaling. Apoptosis 2010;15:183-95.
13. Yi T, Cho SG, Yi Z, Pang X, Rodriguez M, Wang Y, et al. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing Akt and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther 2008;7:1789-96.
14. Gali-Muhtasib H, Kuester D, Mawrin C, Bajbouj K, Diestel A, Ocker M, et al. Thymoquinone triggers inactivation of the stress response pathway sensor CHEK1 and contributes to apoptosis in colorectal cancer cells. Cancer Res 2008;68:5609-18.
15. Li F, Rajendran P, Sethi G. Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway. Br J Pharmacol 2010;161:541-54.
16. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W. From molecular action to physiological outputs: PPAR are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 2006;45:120-59. (Pubitemid 43248732)
17. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-9.
18. Berger J, Moller DE. The mechanism of action of PPARs. Annu Rev Med 2002;53:409-35.
19. Sertznig P, Seifert M, Tilgen W, Reichrath J. Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J Cell Physiol 2007;212:1-12. (Pubitemid 46876399)
20. Yin F, Wakino S, Liu Z, Kim S, Hsueh WA, Collins AR, et al. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem Biophys Res Commun 2001;286:916-22. (Pubitemid 32924859)
21. Kumar AP, Quake AL, Chang MK, Zhou T, Lim KS, Singh R, et al. Repression of NHE1 expression by PPARgamma activation is a potential new approach for specific inhibition of the growth of tumor cells in vitro and in vivo. Cancer Res 2009;69:8636-44.
22. Venkatachalam G, Kumar AP, Yue LS, Pervaiz S, Clement MV, Sakharkar MK. Computational identification and experimental validation of PPRE motifs in NHE1 and MnSOD genes of human. BMC Genomics 2009;10:S5.
23. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998;4:1046-52. (Pubitemid 28417337)
24. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998;58:3344-52. (Pubitemid 28371075)
25. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res 2000;60:1129-38. (Pubitemid 30129556)
26. Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human pancreatic carcinoma cells. Cancer Res 2000;60:5558-64.
27. Elstner E, Müller C, Koshizuka K, Williamson EA, Park D, Asou H, et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998;95:8806-11.
28. Kim KY, Kim SS, Cheon HG. Differential anti-proliferative actions of peroxisome proliferator-activated receptor-g agonists in MCF-7 breast cancer cells. Biochem Pharmacol 2006;72:530-40. (Pubitemid 44163294)
29. Liu H, Zang C, Fenner MH, Possinger K, Elstner E. PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res Treat 2003;79:63-74. (Pubitemid 36561044)
30. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, et al. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 2002;110:923-32.
31. Han S, Roman J. Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics? Anticancer Drugs 2007;18:237-44. (Pubitemid 46192975)
32. Abe A, Kiriyama Y, Hirano M, Miura T, Kamiya H, Harashima H, et al. Troglitazone suppresses cell growth of KU812 cells independently of PPARgamma. Eur J Pharmacol 2002;436:7-13. (Pubitemid 34142392)
33. Lecomte J, Flament S, Salamone S, Boisbrun M, Mazerbourg S, Chapleur Y, et al. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines. Breast Cancer Res Treat 2008;112:437-51.
34. Colin C, Salamone S, Grillier-Vuissoz I, Boisbrun M, Kuntz S, Lecomte J, et al. New troglitazone derivatives devoid of PPARgamma agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone- independent breast cancer cell lines. Breast Cancer Res Treat 2010;124:101-10.
35. Zaytseva YY, Wang X, Southard RC, Wallis NK, Kilgore MW. Down-regulation of PPARgamma1 suppresses cell growth and induces apoptosis in MCF-7 breast cancer cells. Mol Cancer 2008;7:90.
36. Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998;4:1053-7. (Pubitemid 28417338)
37. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004;83:249-89. (Pubitemid 38264873)
38. Zaytseva YY, Wallis NK, Southard RC, Kilgore MW. The PPAR{gamma} antagonist T0070907 suppresses breast cancer cell proliferation and motility via both PPAR{gamma}-dependent and -independent mechanisms. Anticancer Res 2011;31:813-23.
39. Kourtidis A, Srinivasaiah R, Carkner RD, Brosnan MJ, Conklin DS. Peroxisome proliferator-activated receptor-gamma protects ERBB2-positive breast cancer cells from palmitate toxicity. Breast Cancer Res 2009;11:R16.
40. Li F, Fernandez PP, Rajendran P, Hui KM, Sethi G. Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Lett 2010;292:197-207.
41. Chua AW, Hay HS, Rajendran P, Shanmugam MK, Li F, Bist P, et al. Butein downregulates chemokine receptor CXCR4 expression and function through suppression of NF-kB activation in breast and pancreatic tumor cells. Biochem Pharmacol 2010;80:1553-62.
42. Effenberger-Neidnicht K, Schobert R. Combinatorial effects of thymoquinone on the anti-cancer activity of doxorubicin. Cancer Chemother Pharmacol 2011;67:867-74.
43. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, et al. Ligand-binding and coactivator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 1998;395:137-43.
44. Gampe Jr RT, Montana VG, Lambert MH, Miller AB, Bledsoe RK, Milburn MV, et al. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerisation among nuclear receptors. Mol Cell 2000;5:545-55.
45. Salam NK, Huang TH, Kota BP, Kim MS, Li Y, Hibbs DE. Novel PPARg agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study. Chem Biol Drug Des 2008;71:57-70.
46. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43. (Pubitemid 33586866)
47. Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline cardiotoxicity. Cancer Treat Rep 1978;62:873-9.
48. Sethi G, Ahn KS, Aggarwal BB. Targeting NF-kB activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res 2008;6:1059-70.
49. Jafri SH, Glass J, Shi R, Zhang S, Prince M, Kleiner-Hancock H. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: in vitro and in vivo. J Exp Clin Cancer Res 2010;29:87.
50. Badary OA, Nagi MN, Al-Shabanah OA, Al-Sawaf HA, Al-Sohaibani MO, Al- Bekairi AM. Thymoquinone ameliorates the nephrotoxicity induced by cisplatin in rodents and potentiates its antitumor activity. Can J Physiol Pharmacol 1997;75:1356-61. (Pubitemid 28130377)
51. Al-Shabanah OA, Badary OA, Nagi MN, Al-Gharably NM, Al-Rikabi AC, Al- Bekairi AM. Thymoquinone protects against doxorubicin-induced cardiotoxicity without compromising its antitumor activity. J Exp Clin Cancer Res 1998;17:193-8. (Pubitemid 28335578)
52. Arafa ES, Zhu Q, Shah ZI, Wani G, Barakat BM, Racoma I, et al. Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells. Mutat Res 2011;706:28-35.
53. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
54. Torres MP, Ponnusamy MP, Chakraborty S, Smith LM, Das S, Arafat HA, et al. Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies. Mol Cancer Ther 2010;9:1419-31.
55. Carmichael AR. Obesity as a risk factor for development and poor prognosis of breast cancer. Br J Obstet Gynaecol 2006;113:1160-6. (Pubitemid 44401209)
56. Jiang WG, Douglas-Jones A, Mansel RE. Expression of peroxisome- proliferator activated receptor-gamma (PPARgamma) and the PPARgamma co-activator PGC-1, in human breast cancer correlates with clinical outcomes. Int J Cancer 2003;106:752-7. (Pubitemid 36993400)
57. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64. (Pubitemid 34161136)
58. Hau P, Kunz-Schughart L, Bogdahn U, Baumgart U, Hirschmann B, Weimann E, et al. Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas-a phase II study. Oncology 2007;73:21-5. (Pubitemid 351465596)
59. Takayama O, Yamamoto H, Damdinsuren B, Sugita Y, Ngan CY, Xu X, et al. Expression of PPARdelta in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology. Br J Cancer 2006;95: 889-95. (Pubitemid 44498105)
60. Xu L, Han C, Lim K, Wu T. Cross-talk between peroxisomeproliferator- activated receptor delta and cytosolic phospholipase A(2)alpha/cyclooxygenase-2/ prostaglandin E(2) signaling pathways in human hepatocellular carcinoma cells. Cancer Res 2006;66:11859-68. (Pubitemid 46094198)
61. Girroir EE, Hollingshead HE, Billin AN, Willson TM, Robertson GP, Sharma AK, et al. Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. Toxicology 2008;243:236-43. (Pubitemid 350250975)